Supplementary Appendix: Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

Name: Supplementary Appendix: Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Creator: Brett King
Published: 2024-07-17T19:28:55.748Z
Keywords: Dermatology

King, Brett; Senna, Maryanne; Mesinkovska, Natasha; Lynde, Charles; Zirwas, Matthew; Maari, Catherine; Prajapati, Vimal; Sapra, Sheetal; Brzewski, Pawel; Osman, Lawrence; Hanna, Sameh; Wiseman, Marni; Hamilton, Colleen; Cassella, James

doi:10.17632/nmhhzwb96h.1

Supplementary Appendix: Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

Published: 17 July 2024| Version 1 | DOI: 10.17632/nmhhzwb96h.1

Contributors:

Brett King, Maryanne Senna, Natasha Mesinkovska, Charles Lynde, Matthew Zirwas, Catherine Maari, Vimal Prajapati, Sheetal Sapra, Pawel Brzewski, Lawrence Osman, Sameh Hanna, Marni Wiseman, Colleen Hamilton, James Cassella

Description

Supplementary Appendix to: King B, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol 2024

Files

Funding

Sun Pharma (Japan)

Supplementary Appendix: Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

Description

Files

Categories

Funding

Licence